Litcius/Paper detail

Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial

Dean A. Fennell, Amy King, Seid Mohammed, Alastair Greystoke, Sarah Anthony, Charlotte Poile, Nada Nusrat, Molly Scotland, Vina Bhundia, Amy Branson, Cassandra Brookes, Liz Darlison, Alan G. Dawson, Aarti Gaba, Margaret Hutka, Bruno Morgan, Amrita Bajaj, Cathy Richards, Peter Wells-Jordan, Anne Thomas, Dean A. Fennell, Amy King, Alastair Greystoke, Sarah Anthony, Sam Moody, Charlotte Poille, Nada Nusrat, Molly Scotland, Vina Bhundia, Amy Branson, Cassandra Brookes, Liz Darlison, Alan G. Dawson, Aarti Gaba, Margaret Hutka, Bruno Morgan, Amrita Bajaj, Cathy Richards, Peter Wells-Jordan, Adrian Nicolson, Judith Underwood, Azmina Sodha-Ramdeen, Caroline Cowley, Shaun Barber, Anne Thomas

2022The Lancet Oncology81 citationsDOIOpen Access PDF

Topics & Concepts

MedicineMesotheliomaPeritoneal mesotheliomaOncologyInternal medicineCDKN2AClinical endpointPemetrexedHazard ratioChemotherapyClinical trialCancerPathologyCisplatinConfidence intervalOccupational and environmental lung diseasesAdvanced Breast Cancer TherapiesGraphene and Nanomaterials Applications
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial | Litcius